BioPharmSignal logoBioPharmSignal

Biotech News

Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System

Theravance Biopharma (TBPH)Theravance BiopharmaClinical readout

Ampreloxetine clinical development program to be featured in four presentations at the upcoming International Symposium on The Autonomic Nervous System Topline results from the ongoing Phase 3 CYPRESS study of ampreloxetine anticipated in Q1 2026 DUBLIN , Oct.

Related news

TBPHTheravance Biopharma2025-11-20 16:00 EST

Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025

TBPHTheravance Biopharma2025-10-14 10:00 EST

Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting

RVPHReviva Pharmaceuticals2025-10-28 12:00 EST

Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025

RVPHReviva Pharmaceuticals2025-11-12 13:00 EST

Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025

XAIRBeyond Air2026-02-04 13:00 EST

Beyond Cancer Abstract Featuring Phase 1 Data on Intratumoral Ultra-High Concentration Nitric Oxide (UNO) in Solid Tumor Metastases to be Presented at the AACR Annual Meeting 2026

XAIRBeyond Air2026-03-17 20:35 EST

Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial

VERUVeru Inc2026-07-27 12:10 EST

Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

VERUVeru Inc2026-05-13 10:30 EST

Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

INSMInsmed2026-03-23 11:00 EST

Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease

INSMInsmed2026-05-04 11:00 EST

Insmed to Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE® Results from Phase 3b ENCORE Study, at the American Thoracic Society International Conference 2026

View all latest news

Theravance Biopharma

Respiratory Medicines Theravance Biopharma is a biopharmaceutical company whose principal economic asset is a respiratory medicine commercialized through a collaboration. YUPELRI YUPELRI, or revefenacin, is a once-daily nebulized long-acting muscarinic antagonist for maintenance treatment of chronic obstructive pulmonary disease....

Recent company news

TBPHTheravance Biopharma2026-06-29 10:00 EST

THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT

TBPHTheravance Biopharma2026-05-07 12:30 EST

Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

TBPHTheravance Biopharma2026-03-19 12:30 EST

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

TBPHTheravance Biopharma2026-03-03 13:30 EST

Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions

TBPHTheravance Biopharma2025-11-20 16:00 EST

Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025

Stock data

Close
16.92 USD
Market cap
803.2M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States